作者: Samuel T Henderson , Janet L Vogel , Linda J Barr , Fiona Garvin , Julie J Jones
关键词:
摘要: Background Alzheimer's disease (AD) is characterized by early and region-specific declines in cerebral glucose metabolism. Ketone bodies are produced the body during deprivation metabolized brain. An oral ketogenic compound, AC-1202, was tested subjects with probable AD to examine if ketosis could improve cognitive performance.